Specifications
- Purity
- ≥99% (HPLC)
- Appearance
- White to off-white powder
- Identity
- 1H-NMR
Properties
- Solvents
- chloroform, DMSO (10 mg/ml), THF
Available from stock
Etoricoxib
- SKU
- E0092
Categories:
- Synonyms
- L-791,456 , MK-0663 , MK 663 , 5-Chloro-3-[4-(methylsulfonyl)phenyl]-2-(2-methyl-5-pyridinyl)pyridine , 5-Chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine
- 202409-33-4
- CAS-Number
- C18H15ClN2O2S
- Molecular Formula
- 358.84
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- +4°C
- Long Term Storage
- +4°C
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at +4°C.
- Hazard statements
- H302-H310
- Precautionary statements
- P280-P302 + P350-P310
- GHS Symbol
- GHS06
- Signal word
- Danger
- RIDADR
- UN2811 6.1
- Transportation
- Packing Group II
- Description
- Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) and a potent cyclooxygenase-2 (COX-2) inhibitor. This dipyridinyl compound demonstrates high in vitro and ex vivo selectivity for COX-2 over COX-1 in several assays. Used to treat patients suffering from osteoarthritis and rheumatoid arthritis. Might have some chemopreventive properties.
- Smiles
- O=S(C1=CC=C(C2=CC(Cl)=CN=C2C3=CC=C(C)N=C3)C=C1)(C)=O
- InChi Key
- MNJVRJDLRVPLFE-UHFFFAOYSA-N
- References
- (1) D. Riendeau, et al., J. Pharmacol. Exper. Therap. 296, 558 (2001) , (2) P.L. McGeer, et al., Exp. Gerontol. 37, 925 (2002) , (3) R. Chenevard, et al., Circulation 107, 405 (2003) , (4) A. Dallob,et al., J. Clin. Pharmacol. 43, 573 (2003) , (5) P. Patrignani, et al., Expert Opin. Pharmacother. 4, 265 (2003) , (6) S.D. Martina, et al., Ann. Pharmacother. 39, 854 (2005) , (7) T. Tanwar, et al., Eur. J. Cancer Prev. 19, 280 (2010) , (8) T. Tanwar, et al., Asian Pac. J. Cancer Prev. 11, 1329 (2010)
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) and a potent cyclooxygenase-2 (COX-2) inhibitor. This dipyridinyl compound demonstrates high in vitro and ex vivo selectivity for COX-2 over COX-1 in several assays. Used to treat patients suffering from osteoarthritis and rheumatoid arthritis. Might have some chemopreventive properties.
Additional information
| Synonyms | L-791,456, MK-0663, MK 663, 5-Chloro-3-[4-(methylsulfonyl)phenyl]-2-(2-methyl-5-pyridinyl)pyridine, 5-Chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine |
|---|---|
| Purity | ≥99% (HPLC) |
| Appearance | White to off-white powder |
| CAS-Number | 202409-33-4 |
| Molecular Formula | C18H15ClN2O2S |
| Molecular Weight | 358.84 |
| Identity | 1H-NMR |
| Solvents | chloroform, DMSO (10 mg/ml), THF |
| Smiles | O=S(C1=CC=C(C2=CC(Cl)=CN=C2C3=CC=C(C)N=C3)C=C1)(C)=O |
| InChi Key | MNJVRJDLRVPLFE-UHFFFAOYSA-N |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Hazard statements | H302-H310 |
| Precautionary statements | P280-P302 + P350-P310 |
| GHS Symbol | GHS06 |
| Signal word | Danger |
| RIDADR | UN2811 6.1 |
| Transportation | Packing Group II |
| References | (1) D. Riendeau, et al., J. Pharmacol. Exper. Therap. 296, 558 (2001), (2) P.L. McGeer, et al., Exp. Gerontol. 37, 925 (2002), (3) R. Chenevard, et al., Circulation 107, 405 (2003), (4) A. Dallob,et al., J. Clin. Pharmacol. 43, 573 (2003), (5) P. Patrignani, et al., Expert Opin. Pharmacother. 4, 265 (2003), (6) S.D. Martina, et al., Ann. Pharmacother. 39, 854 (2005), (7) T. Tanwar, et al., Eur. J. Cancer Prev. 19, 280 (2010), (8) T. Tanwar, et al., Asian Pac. J. Cancer Prev. 11, 1329 (2010) |
| Quantity | 25 mg, Bulk |
